Skip to content
Skip to search
Skip to footer
- ACM IC14- Phase 1b to Evaluate the Safety, Pharmacokinetics and preliminary efficacy of Atibuclimab (IC14, Monoclonal Antibody Against CD14) in patients with Arrhythmogenic Cardiomyopathy. Phillip Cuculich, MD. Implicit Biosciences.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- BACKBEAT- BradycArdia paCemaKer with AV interval modulation for Blood prEssure treAtmenT. Daniel Cooper, MD. Orchestra Biomed.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- CNCR REGISTRY: A multi-center registry looking at patient outcomes for patients treated with cardiac radioablation. Pamela Samson, MD. Washington University.
- LEADR- Lead EvaluAtion for Defibrillation and Reliability, Prospective, multi-center, single-arm, non-randomized, Bayesian, adaptive study design, pre-market, interventional pivotal clinical study. Timothy Smith, MD. Medtronic.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- LIBREXIA-AF: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation. Marye Gleva MD. Washington University.
IN FOLLOW-UP
view on clinicaltrials.gov
- RADIATE-VT: A study evaluating the safety and efficacy of cardiac radioablation compared to catheter ablation in patients with ventricular tachycardia. Daniel Cooper, MD. Varian Medical Systems.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- REACT AF- Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation. Thomas Maddox, MD. Federal Grant/Northwestern.
CURRENTLY ENROLLING
view on clinicaltrials.gov
- VIBRANT-AF: Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation. Daniel Cooper MD. Washington University.
CURRENTLY ENROLLING
view on clinicaltrials.gov